PLSE

Pulse Biosciences, Inc. (PLSE) - 10-K Summary

Business Context and Reporting Period

Company: Pulse Biosciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Pulse is a bioelectric medicine company developing Nano-pulse Stimulation (NPS) technology, specifically Nanosecond Pulsed-Field Ablation (nsPFA). The company has shifted its primary focus from dermatology to cardiology (treatment of atrial fibrillation) and surgical soft tissue ablation. Key products include the CellFX Console, the nsPFA Percutaneous Electrode System (FDA cleared in 2024), and the nsPFA Cardiac Clamp and 360° Cardiac Catheter (in clinical development).

Key Financial Metrics (Year Ended Dec 31, 2024)

Note: The company reported no product revenues for 2024 or 2023. The company is a "smaller reporting company" and does not provide selected financial data tables.

Material Changes vs. Prior Period

• Increased Losses: Net loss increased by $11.4 million (27%) to $53.6 million, driven by higher operating expenses.
• Expense Growth: R&D expenses rose $4.5 million (16%) due to increased stock-based compensation ($2.8M), personnel costs ($1.6M), and supplies ($0.7M). G&A expenses rose $8.1 million (52%) primarily due to stock-based compensation ($3.6M), a legal settlement ($1.2M), and severance costs ($0.7M).
• Liquidity Improvement: Cash and cash equivalents more than doubled to $118.0 million, fueled by a $60 million rights offering and $49.4 million in warrant exercises during 2024.
• Interest Income: Net interest income increased to $2.7 million from $1.4 million due to higher cash balances and interest rates.

Guidance, Outlook, and Risks

Outlook and Milestones:

• Soft Tissue: The nsPFA Percutaneous Electrode System received FDA 510(k) clearance in March 2024. The company has placed systems at 8 U.S. sites with over 70 procedures completed. A pivotal clinical trial for benign thyroid nodules is expected to commence in mid-2025.
• Cardiology: The nsPFA Cardiac Clamp received FDA Breakthrough Device Designation in July 2024. A pivotal clinical trial for atrial fibrillation (AF) is expected to begin in mid-2025. The nsPFA 360° Cardiac Catheter study is nearly fully enrolled (80+ patients), with a U.S. pivotal study also expected in mid-2025.
• Capital Needs: Management believes current cash ($118M) is sufficient for at least 12 months but explicitly states the need for additional capital to fund operations and complete development.

Key Risks and Contingencies:

• Profitability: The company has incurred significant losses since inception and expects to continue doing so for several years. There is no assurance it will ever achieve profitability.
• Regulatory Approval: Future success depends on FDA PMA approvals for cardiac devices, which are not guaranteed and require extensive clinical data.
• Concentration of Ownership: Co-Chairman Robert W. Duggan owns approximately 73% of the voting power, limiting minority shareholder influence and potentially deterring acquisition.
• Financing: Continued reliance on equity financing (primarily from Mr. Duggan) may result in dilution. Failure to secure funding could force operational curtailment.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $118M cash balance against the projected burn rate for the upcoming pivotal trials in 2025.
• Regulatory Pathways: Confirm the specific FDA requirements for the PMA applications for the Cardiac Clamp and Catheter, as these are high-risk Class III devices.
• Commercial Pilot Data: Review the clinical outcomes and adoption rates from the 8 U.S. sites currently using the Percutaneous Electrode System.
• Related Party Transactions: Assess the terms and impact of the 2024 Rights Offering, where the Co-Chairman purchased 88% of the units, and the potential for future dilution.
• Stock-Based Compensation: Monitor the impact of the $13.6M stock-based compensation expense, particularly the modifications to performance-based options in late 2024.